Incontestable epidemiological trends show that, for the foreseeable future, mortality and morbidity will be dominated by an escalation in chronic lifestyle-related diseases. Exercise training (ET) elicits a wide range of health benefits that improve the health and well-being of individuals with chronic disease, 1 and the 'exercise pill' is a wonder drug that has the power to benefit the whole body system.
Incontestable epidemiological trends show that, for the foreseeable future, mortality and morbidity will be dominated by an escalation in chronic lifestyle-related diseases. Exercise training (ET) elicits a wide range of health benefits that improve the health and well-being of individuals with chronic disease, 1 and the 'exercise pill' is a wonder drug that has the power to benefit the whole body system. 2 ET has very few contraindications or adverse effects 3 and regular exercise has been shown to be as effective as most medically prescribed drugs [4] [5] [6] [7] in reducing the death rate from the major cardiovascular diseases (CVDs). The more of the exercise pill you take, the healthier you will be.
Today, several guidelines and meta-analyses are available, [7] [8] [9] [10] [11] [12] [13] and ET can be prescribed in CVD patients 14 in an individual approach; thus, after careful examination, ET should be prescribed in all CVD patients. Nonetheless, a real one-size-fits-all approach is not available, and this might contribute to underutilisation of exercise-based cardiac rehabilitation. 3, 6 ET prescription in different combinations according to the severity and type of CVD, risk factors and comorbidity coexistence, with different goals to be accomplished, is needed in order to tackle real-life encounters and to meet their exigencies. The European Association of Preventive Cardiology EXPERT (EXercise Prescription in Everyday practice and Rehabilitative Training) tool might help: Hansen and his group should be congratulated for creating this instrument that aims to optimise exercise prescription in all CVD patients. 15 In 2013, more than 30 ET experts (the EXPERT working group) agreed to collaborate, and they derived data for different CVD diseases, risk factors and comorbidities based on guidelines and expert opinions in order to construct an algorithm. The included CVDs in this flow chart were: (a) angina pectoris; (b) coronary artery disease (CAD) with recent coronary artery bypass graft; (c) CAD with recent percutaneous coronary intervention; (d) CAD with acute myocardial infarction; (e) heart failure (HF) with lowered left ventricular ejection fraction; (f) HF with preserved left ventricular ejection fraction; (g) peripheral artery disease; (h) pacemaker/implantable cardioverter defibrillator; (i) assist devices; (j) cardiac transplantation; (k) valve surgery without coronary artery bypass graft; and (l) congenital heart disease. CVD risk factors involved were: (a) hypertension; (b) dyslipidaemia; (c) insulin resistance/type 2 diabetes; (d) type 1 diabetes; and (e) obesity. Finally, exercise modifiers and factors/chronic diseases that significantly affect the content of rehabilitation intervention were considered, such as: (a) cardiac resynchronisation therapy for HF patients with reduced left ventricular ejection fraction; (b) pulmonary hypertension; (c) chronic lung disease; and (d) renal failure and sarcopenia/frailty. 15, 16 The EXPERT algorithm was proposed to support prescription, as it automatically provides an exercise prescription in an integrated fashion and in practice. This tool also considers the baseline exercise tolerance, common cardiovascular medications and occurrence of adverse events during exercise testing. 16 Details and instructions on how to use it have been meticulously explained, 15, 16 and now the EXPERT tool is available on a website (https://www.escardio.org/Education/ Practice-Tools/CVD-prevention-toolbox/EXPERTTool).
To verify the EXPERT tool's application and functioning versus traditional ways of acting, Hansen et al. 17 analysed ET prescriptions in five patient cases, from the easiest (case 1) to the most difficult (case 5). Participants were incompletely involved in the EXPERT working group, but were all actively involved in CVD rehabilitation. Most were cardiologists, while fewer were physiotherapists, cardiovascular rehabilitation scientists, physiatrists and sports physicians, general practitioners, rehabilitation physicians and exercise physiologists. Specialists were requested to specify exercise intensity, exercise frequency, programme duration, exercise session duration and whether strength training exercises were prescribed thereafter, and from these details, total exercise volume was calculated. First, the variance in exercise prescription between clinicians was calculated for every case separately, then ET prescriptions that were generated by the clinicians were compared with prescriptions generated by the EXPERT tool. A large inter-clinician variance for all ET components was evident, 17 and ET prescriptions were significantly different between clinicians and the EXPERT tool. Although the EXPERT tool is not proven to be a 'gold standard', these findings confirm the need for a mixed and integrated attitude of ET prescription in order to favour a daily life approach together with the importance of standardisation in CVD rehabilitation. Although different factors might influence ET prescriptions variance, with some being reversible (clinician adherence to, or knowledge of, clinical guidelines, different habits and education), while others are unalterable (different national exercise guidelines and international recommendations, legal or environmental constraints; that is, organisation of the rehabilitation units both in and between countries), the EXPERT tool can help. The EXPERT tool proposes an integrated technique for ET prescriptions, especially in patients with multiple CVDs and risk factors, and it might be valuable in the creation of a proper training environment for neophyte clinicians.
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